Grifols’ R+D+i strategy promotes a holistic approach that encompasses both in-house projects and investee-led initiatives that complement the company’s operations. Grifols considers investments and collaborations with third parties as an extension of its R+D+i efforts.
Grifols Innovation Office is responsible for spearheading the company’s R+D+i strategy. It evaluates and expedites research projects, oversees the development of innovative treatments, products and services, and promotes continuous improvement of existing products and operations. It also nurtures ties with key agents in the innovation ecosystem, including academic and research institutions.
Grifols Innovation Office encompasses three main domains: Grifols Innovation and New Technology (GIANT), which manages the group’s investments in R+D+i firms and research-related initiatives; the Scientific and Medical Affairs area; and the Patents and Trademarks Department.
Grifols Innovation Office liaises with the different functional areas of the group and presents projects to the interdisciplinary committees for review, guaranteeing a complete analysis. Defined by therapeutic areas, these in-house committees convene regularly to assess the projects and identify, evaluate and prioritize new opportunities.
Grifols also has a Scientific Review Board, which monitors and reviews the progress of in-house research initiatives from a technical standpoint and assesses the potential value of research opportunities in Grifols’ investees. This cross-functional committee is composed of members of Grifols Innovation Office, clinical R+D+i areas and corporate divisions.